Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Adenoviral Interferon α2b
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intravesical
01
Overview
Recombinant Adenoviral Interferon α2b (Ad-IFN) is a gene therapy that utilizes a recombinant adenovirus to deliver the gene encoding interferon α2b. This leads to the production of interferon-alpha (IFNα) in the target tissue. It is formulated with the excipient Syn3 and has been investigated for intravesical administration in nonmuscle invasive bladder cancer.
- Other names
- adenoviral interferoninterferon-alpha
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on recombinant Adenoviral Interferon α2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Adenoviral Interferon α2b.